DP
CNTA

Diadema Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Diadema Partners’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,100
Closed -$528K – 158
2025
Q4 		$528K Buy
+21,100
New +$534K 0.09% 115

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Diadema Partners's CNTA Position: Q1 2026 in Review

Diadema Partners sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 90,000 shares — an estimated $2.25M sold.

Diadema Partners first reported a position in CNTA in Q4 2024 and held it in 3 quarters. The position peaked at $2.36M in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Diadema Partners reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 90,000 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2.25M.
  • Diadema Partners first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Diadema Partners's Centessa Pharmaceuticals position peaked at $2.36M in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.